news
AKT degrader may become a new, effective treatment for many cancers
Researchers have discovered a therapeutic agent that is effective in vitro at disrupting a biological pathway that helps cancer survive.
List view / Grid view
Immuno-oncology
news
Inhibiting PIP4K enzymes could help immune system fight cancer
Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
news
Personalised organoid models may improve immunotherapy treatment
Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
article
Lentiviral vectors: the key to cancer treatments that CAR T-cell therapy cannot reach?
Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.
news
Protein activation discovery could widen access to cancer immunotherapy
The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
news
Natural killer cell immunotherapy shows promise against melanoma
Researchers have shown that natural killer cell immunotherapy effectively treated mice harbouring human melanoma tumours.
article
The other end of the antibody: Fc biology and immunotherapy
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
news
Common antidepressant drugs fight cancer in mice, study shows
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
article
Off-the-shelf T-cell therapy from gene edited stem cells
Dr Jo Brewer outlines research into allogeneic products by gene editing stem cells, which has the potential to build a broad family of multiple immune cell types, including T-cell therapies.
news
Newly identified protein could become target for cancer immunotherapy
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
news
Natural killer cells and bispecific antibody target lymphoma tumours
In pre-clinical studies, researchers showed that cord blood-derived natural killer cells and a bispecific antibody eliminated lymphoma cells.
news
Team identifies paediatric acute myeloid leukaemia drug target
Researchers have found that the gene mesothelin can be targeted by new antibody-drug conjugates to treat acute myeloid leukaemia in children.
article
New developments in the research field of immuno-oncology
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
webinar
Imaging Mass Cytometry™ of malignant tissue architecture: rare single cells to structured multi-cellular communities
14 April 2021 | By Fluidigm
Watch our free on-demand webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.
article
Immunosurveillance and the importance of CD4 T cells in developing cancer vaccines
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
